Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 885-904

  Kretzer, Iara F ^a,b   Maria, Durvanei A ^c   Guido, Maria C ^a   Contente, Thaís C ^a   Maranhão, Raul C ^a,b  

^a Laboratory of Metabolism and Lipids   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

Author keywords

B16F10 melanoma; Cancer treatment; Drug delivery; Lipid nanoparticles; Statins

Indexed keywords

CYCLIN D1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; LIPID NANOEMULSION; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOCARRIER; PACLITAXEL; PROTEIN P21; PROTEIN P27; SIMVASTATIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B16F10 MELANOMA; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL DENSITY; COLLAGEN FIBER; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSPLANTABLE SOLID TUMORS; TREATMENT DURATION; TUMOR VASCULARIZATION; WEIGHT REDUCTION; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYME IMMUNOASSAY; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHOLESTEROL, LDL; DRUG SYNERGISM; FEMALE; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; LIPIDS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PACLITAXEL; RECEPTORS, LDL; SIMVASTATIN; TUMOR CELLS, CULTURED;

EID: 84960382116     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–438.
2. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978;52(6):1099–1114.
3. Maranhão RC, Garicochea B, Silva EL, Llacer PD, Pileggi FJ, Chamone DA. Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz J Med Biol Res. 1992;25(10):1003–1007.
4. Maranhão RC, Garicochea B, Silva EL, et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipo­protein in patients with acute leukemia. Cancer Res. 1994;54(17):4660–4666.
5. Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol. 2006;57(5):624–630.
6. Vitols S, Angelin B, Ericsson S, et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci U S A. 1990;87(7):2598–2602.
7. Rudling MJ, Ståhle L, Peterson CO, Skoog L. Content of low density lipoprotein receptors in breast cancer tissue related to survival of patients. Br Med J (Clin Res Ed). 1986;292(6520):580–582.
8. Avall-Lundqvist EH, Peterson CO. Serum cholesterol and apolipo­protein B levels may reflect disease activity in ovarian cancer patients. Acta Oncol. 1996;35(8):1007–1010.
9. Ades A, Carvalho JP, Graziani SR, et al. Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol Oncol. 2001;82(1):84–87.
10. Graziani SR, Igreja FA, Hegg R, et al. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol. 2002;85(3):493–497.
11. Lundberg B. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. Cancer Res. 1987;47(15):4105–4108.
12. Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids. 1993;28(8):691–696.
13. Dorlhiac-Llacer PE, Marquezini MV, Toffoletto O, Carneiro RC, Maranhão RC, Chamone DA. In vitro cytotoxicity of the LDE: dauno­rubicin complex in acute myelogenous leukemia blast cells. Braz J Med Biol Res. 2001;34(10):1257–1263.
14. Maranhão RC, Graziani SR, Yamaguchi N, et al. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol. 2002;49(6):487–498.
15. Rodrigues DG, Covolan CC, Coradi ST, Barboza R, Maranhão RC. Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. J Pharm Pharmacol. 2002;54(6):765–772.
16. Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CH, Rodrigues DG, Maranhão RC. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol. 2003;55(12):1615–1622.
17. Rodrigues DG, Maria DA, Fernandes DC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 2005;55(6):565–576.
18. Teixeira RS, Valduga CJ, Benvenutti LA, Schreier S, Maranhão RC. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J Pharm Pharmacol. 2008;60(10):1287–1295.
19. Contente TC, Kretzer IF, Filippin-Monteiro FB, Maria DA, Maranhão RC. Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice. J Pharm Pharmacol. 2014;66(12):1698–1709.
20. Teixeira RS, Curi R, Maranhão RC. Effects on Walker 256 tumour of carmustine associated with a cholesterol-rich microemulsion (LDE). J Pharm Pharmacol. 2004;56(7):909–914.
21. Lo Prete AC, Maria DA, Rodrigues DG, Valduga CJ, Ibañez OC, Maranhão RC. Evaluation in melanoma-bearing mice of an etoposide deriv­ative associated to a cholesterol-rich nano-emulsion. J Pharm Pharmacol. 2006;58(6):801–808.
22. Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother Pharmacol. 2007;59(1):105–111.
23. Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipo­protein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol. 2009;63(2):281–287.
24. Soma MR, Baetta R, De Renzis MR, et al. In vivo enhanced antitumor activity of carmustine [N,N’-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res. 1995;55(3):597–602.
25. Feleszko W, Zagozdzon R, Gołab J, Jakóbisiak M. Potentiated antitu­mour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer. 1998;34(3):406–411.
26. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999;5(8):2223–2229.
27. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and pacli­taxel in human cancer cells. Mol Cancer Ther. 2001;1(2):141–149.
28. Werner M, Sacher J, Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol. 2004;143(6):715–724.
29. Kozar K, Kaminski R, Legat M, et al. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol. 2004;24(5):1149–1157.
30. Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochem Pharmacol. 2008;75(4):907–913.
31. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer. 2010;10:103.
32. Mol MJ, Erkelens DW, Leuven JA, Schouten JA, Stalenhoef AF. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholestero­laemia. Lancet. 1986;2(8513):936–939.
33. Alberts AW. Lovastatin and simvastatin – inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology. 1990;77 4:14–21.
34. Tobert JA. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circula­tion. 1987;76(3):534–538.
35. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105(6):739–745.
36. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC iso­prenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther. 2003;2(10):941–948.
37. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930–942.
38. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17(1):88–94.
39. Favero GM, Otuki MF, Oliveira KA, et al. Simvastatin impairs murine melanoma growth. Lipids Health Dis. 2010;9:142.
40. Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26(5): 735–741.
41. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ. Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems. 3rd ed. Bethesda (MD): National Institutes of Health; 1972.
42. Versluis AJ, van Geel PJ, Oppelaar H, van Berkel TJ, Bijsterbosch MK. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br J Cancer. 1996;74(4):525–532.
43. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–430.
44. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005;118(Pt 5):843–846.
45. Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol. 2009;64(4):657–663.
46. Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis AD, Richardson A. Preclinical evaluation of statins as a treatment for ovar­ian cancer. Gynecol Oncol. 2013;129(2):417–424.
47. Fernández C, Lobo M, Gómez-Coronado D, Lasunción MA. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp Cell Res. 2004;300(1):109–120.
48. Griffiths B, Lewis CA, Bensaad K, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1(1):3.
49. Lee BH, Taylor MG, Robinet P, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 2013;73(3):1211–1218.
50. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–398.
51. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep. 2008;10(5):439–446.
52. Labrousse AL, Ntayi C, Hornebeck W, Bernard P. Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol. 2004;49(3):269–275.
53. Wandel E, Raschke A, Hildebrandt G, et al. Fibroblasts enhance the invasive capacity of melanoma cells in vitro. Arch Dermatol Res. 2002;293(12):601–608.
54. Glynn SA, O’Sullivan D, Eustace AJ, Clynes M, O’Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors simvas­tatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer. 2008;8:9.
55. Relja B, Meder F, Wang M, et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011;38(3):879–885.
56. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res. 2005;11(21):7629–7636.
57. Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol. 2007;127(8):2031–2041.
58. Koga M, Kai H, Egami K, et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun. 2008;365(2):279–284.
59. Johnson JP, Stade BG, Holzmann B, Schwäble W, Riethmüller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A. 1989;86(2):641–644.
60. Slattery MJ, Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer. 2003;106(5):713–722.
61. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC Cancer. 2012;12:455.
62. Johnsen M, Lund LR, Rømer J, Almholt K, Danø K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degrada­tion. Curr Opin Cell Biol. 1998;10(5):667–671.
63. Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoat­tractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005;111(11):1439–1447.
64. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modu­lates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188(1):51–58.
65. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford). 2009;48(3):233–242.
66. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol. 1998;51(1):1–7.
67. Coupland SE, Bechrakis N, Schüler A, et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal mela­noma and retinoblastoma. Br J Ophthalmol. 1998;82(8):961–970.
68. Inohara S, Kitagawa K, Kitano Y. Expression of cyclin D1 and p53 protein in various malignant skin tumors. Dermatology. 1996;192(2):94–98.
69. Driscoll B, Buckley S, Barsky L, Weinberg K, Anderson KD, Warburton D. Abrogation of cyclin D1 expression predisposes lung cancer cells to serum deprivation-induced apoptosis. Am J Physiol. 1999;276(4 Pt 1):L679–L687.
70. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62(11):3200–3206.
71. Ukomadu C, Dutta A. P21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem. 2003;278(44):43586–43594.
72. Denoyelle C, Albanese P, Uzan G, et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003;15(3):327–338.
73. Takeda I, Maruya S, Shirasaki T, et al. Simvastatin inactivates β1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007;98(6):890–899.
74. Saito A, Saito N, Mol W, et al. Simvastatin inhibits growth via apop­tosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008;18(2):85–94.
75. Lourenço-Filho DD, Maranhão RC, Méndez-Contreras CA, Tavares ER, Freitas FR, Stolf NA. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model. J Thorac Cardiovasc Surg. 2011;141(6):1522–1528.
76. Quimby FW, Luong RH. Clinical chemistry of the laboratory mouse. In: Fox JG, Davisson MT, Quimby FW, Barthold SW, Newcomer CE, Smith AL, editors. The Mouse in Biomedical Research. 2nd ed. Burlington (MA): Academic Press; 2007:171–216.
77. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med. 1964;114(4):497–500.
78. Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol. 1998;19(1):82–84.
79. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9(3):287–291.
80. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol. 2002;3(7):425–430.
81. Nolte I, Przibylla H, Bostel T, Groden C, Brockmann MA. Tumor-platelet interactions: glioblastoma growth is accompanied by increasing platelet counts. Clin Neurol Neurosurg. 2008;110(4):339–342.
82. Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J. 2003;145(3):387–396.
83. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–581.
84. Kretzer IF, Maria DA, Maranhão RC. Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion. Cell Oncol (Dordr). 2012;35(6):451–460.